Key Developments

In October 2023,Novartis, apharmaceutical corporation has presented Phase III PSMAfore trial data at the 2023 European Society for Medical Oncology (ESMO) Congress. The data, highlighted in the Presidential Symposium, demonstrate that Pluvicto (lutetium (177Lu) vipivotide tetraxetan) achieved its primary endpoint by significantly improving radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who had previously received androgen receptor pathway inhibitor (ARPI) therapy, compared to a change in ARPI alone.
In August 2023,The USFDA granted approval, for Akeega (niraparib and abiraterone acetate) in a fixed-dose combination with prednisone. This approval is for adult patients diagnosed with deleterious or suspected deleterious BRCA-mutated castration-resistant prostate cancer (mCRPC), confirmed by an FDA-approved test.
In February 2023, Pfizer,pharmaceutical and biotechnology corporationannounced today that the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib), an oral PARP inhibitor, in combination with XTANDI(enzalutamide), has shown positive results. The study demonstrated a statistically significant and clinically meaningful enhancement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC).
In June 2023, AstraZeneca ,biopharmaceuticalCompany and MSD's Lynparza (olaparib), in combination with abiraterone and prednisone or prednisolone, has received US approval for treating adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC).